The FDA has approved Uplizna (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease in adult patients.

A 43-year-old woman presented with 6 months of recurrent bilateral eye pain and redness alongside spontaneous urticaria.She ...

Explore holistic approaches to treating the atopic triad in children—eczema, asthma, and allergies—with naturopathic ...

With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate formulated with the AmorphOX technology.

Epsilogen has acquired antibody developer TigaTx in a deal that collates work from the companies’ alternative antibody isotopes for cancer.

Epsilogen completes acquisition of TigaTx to create world’s leading pan-isotype cancer antibody company: London Tuesday, April 8, 2025, 10:00 Hrs [IST] Epsilogen, the global lea ...

The combined company will clinically advance Epsilogen's MOv18 IgE antibody in ovarian cancer and TigaTx's anti-EGFR IgA antibody.

Looking ahead, Epsilogen sees the deal as giving it the option to “mix and match IgE, IgA and IgG functionality into a single antibody molecule.” “Such hybrid antibodies have the potential ...

Data from a Phase I trial found it to be safe and well tolerated with early signs of clinical activity EPS 401 (formerly TIGA-001), an anti-EGFR IgA antibody with IND-enabling studies underway ...

UK-based developer of novel immunoglobulin E (IgE) antibodies to treat cancer, Epsilogen, says it has completed the acquisition of TigaTx, a Boston, USA-based biotechnology company developing ...